Adebrelimab
- Generic Name
- Adebrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 36
- Registration Number
- NCT06299371
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Lei ZHAO
- Target Recruit Count
- 20
- Registration Number
- NCT06296563
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 36
- Registration Number
- NCT06282445
- Locations
- 🇨🇳
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China
The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Hospital of Stomatology, Wuhan University
- Target Recruit Count
- 35
- Registration Number
- NCT06277791
- Locations
- 🇨🇳
School of Stomatology Wuhan University, Hubei, Wuhan, China
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 288
- Registration Number
- NCT06267170
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06266832
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 60
- Registration Number
- NCT06261125
- Locations
- 🇨🇳
Mian Xi, Guangzhou, Guangdong, China
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
- Conditions
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06251492
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center Xiamen Branch., Xiamen, Fujian, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06236997
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital, Tongji Medical College，Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-01-29
- Target Recruit Count
- 182
- Registration Number
- NCT06229067
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.